Bellafill® Proved to Be Safe and Effective Through 5 Years

bellafill_logoDr. Paul LoVerme and our team are pleased to announce that Bellafill® has become the first – and only – FDA-approved dermal filler proven to help reduce the appearance of nasolabial folds (smile lines) with safe and effective results through five years of post-approval study. In a recent press release syndicated by Suneva Medical, Inc. (makers of Bellafill®), the aesthetics company stated, “The study marks the largest and longest prospective dermal filler study ever conducted, with unprecedented retention, high patient satisfaction and strong evidence to support the long-term safety and effectiveness of Bellafill®.”

Injected underneath targeted nasolabial fold(s), Bellafill® helps to create an ideal foundation for long-lasting wrinkle correction. Once administered, the filler’s innovative solution works to provide structure around which the body can build new collagen for a rejuvenated appearance on the skin’s surface. Depending on the depth of the wrinkle or fold, desired outcomes are often achieved with only one to two virtually painless treatments, and most individuals are able to resume normal activities immediately. In addition to nasolabial folds, Bellafill® can also be used to add volume to marionette lines, augment the midfacial region, fill in acne scars and smooth out other depressions in the skin.

Ultimately, the long-term safety and efficacy demonstrated in the results of this five-year study make Bellafill® truly a revolutionary dermal filler. If you would like to learn more about this advanced injectable treatment, or if you are interested in scheduling a consultation with Dr. LoVerme, please contact us today.

Vectra 3D Imaging

We can capture imagery of your body in 3D, and provide an extremely realistic view of how your post-surgery shape will be.

Learn More

ZO® Skin Health Inc.The Next Generation of Skin Health Solution

Purchase Products


Learn more about your procedure, our practice, and view photos taken during your consultation.